A More Detailed Image of Alzheimer's Disease
This article was originally published in Start Up
Executive Summary
Even as researchers continue the debate around whether the plaque formation characteristic of Alzheimer's Disease precedes or follows the neurological abnormalities that eventually cause dementia, a new imaging study has shown that plaques are a critical mediator in AD development, bolstering the notion that removing them or ultimately targeting the processes that lead to plaque formation are valid therapeutic strategies.
You may also be interested in...
FDA, Pharma Need To Take Next Step In Alzheimer’s Imaging Tools
Even with consensus on a path forward for imaging agents to be validated for detection of amyloid-beta, there are still questions about the clinical utility of the agents and the potential path toward their use in diagnosis of, or prognosis for, Alzheimer's disease
Alzheimer’s Imaging Agents Should Be Validated With Autopsies, Panel Says
Autopsy is the gold standard for confirming a diagnosis of Alzheimer's disease and should be used as the standard of truth in studies of imaging agents hoping to gain approval for amyloid plaque detection, an FDA panel unanimously concluded
Alzheimer’s Imaging Agents Should Be Validated With Autopsies, Panel Says
Autopsy is the gold standard for confirming a diagnosis of Alzheimer's disease and should be used as the standard of truth in studies of imaging agents hoping to gain approval for amyloid plaque detection, an FDA panel unanimously concluded